Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Resignation of Directors
On and effective May 24, 2023, Michelle Yanez gave notice to Inhibitor
Therapeutics, Inc. (the "Company") of her resignation from the Board of
Directors of the Company (the "Board"). Ms. Yanez's resignation from the Board
is due to her acceptance of a full time chief financial officer position at a
different company and is not based on any disagreement with the Company on any
matter relating to the Company's operations, policies or practices.
Appointment of Director
On May 24, 2023, the Board of the Company appointed Michael Jerman, CPA. as an
independent member of its Board. Mr. Jerman will serve as a member and Chairman
of the Board's Audit committee.
Mr. Jerman (a) is not a party to any arrangement or understanding with any other
person pursuant to which he was selected as a director of the Company and (b)
has not been involved in any transaction with the Company that would require
disclosure under Item 404(a) of the Regulation S-K.
Below is Mr. Jerman's biography:
Mr. Jerman, age 39, has previously been a chief financial officer of multiple
private equity-backed companies in the energy, SaaS, and manufacturing
industries; was a Director with PwC in the US and UK; was a Captain with the
United States Air Force. He has led global public and private client engagements
in the industries of retail and consumer, energy, utilities and mining, and
transportation and logistics. Mr. Jerman has significant experience in client
equity and debt offerings, business combinations inclusive of public listing and
reporting requirements, initial valuations and ongoing goodwill impairment
analyses, share-based awards, restructuring, and global taxes, as well as
stakeholder management, specifically with board and management presentation
experience to include annual and quarterly requirements, fee negotiations,
technical accounting and finance discussions, and fraud and non-compliance
investigations. Mr. Jerman has specialized in rapid project mobilization and
deployment of skilled resources for emergency issues, design, and implementation
of small to large scale assurance requirements and advisory projects. Mr.
Jerman's additional experience includes leading PwC's latest data acquisition
methods and tools, client acquisitions and systems implementations to include
new SOX-compliant control plan implementations across multiple systems, leading
co-sourced internal audit projects, and time spent driving PwC's lean efficiency
initiatives. Mr. Jerman was a member of the PwC national office within the SEC
PCAOB quality group supporting Europe and the EMEA regions with complex
accounting and audit consultations. The Company believes Mr. Jerman is qualified
to serve on the Board and as a qualified financial expert on the Company's Audit
Committee due to his substantial experience with the SEC PCAOB quality group at
PwC and his experience assisting public reporting companies with their annual
and quarterly requirements.
2
© Edgar Online, source Glimpses